The Challenge
RealTime Laboratories, a U.S. biotech lab specializing in mycotoxin testing, made its urine mycotoxin panel available to consumers at home for the first time in early 2026. The company needed to reach two very different audiences at once: the functional medicine providers and laboratory professionals who order and evaluate its tests, and consumers just beginning to ask whether mold in their homes could be affecting their health. Mold-related illness is still an emerging and sometimes debated topic, so RealTime needed coverage that built trust with clinicians while making the subject accessible to everyday consumers.
The Goal
AM PR built a program that paired clinical credibility with consumer reach. On the clinical side, AM PR secured physician Q&As and expert commentary in laboratory, pathology, and physician-facing outlets, announcing RealTime’s expanded 31-marker panel to lab industry trade press. On the consumer side, AM PR positioned Dr. Onah as an expert voice on mold and healthy homes, tying commentary to seasonal and timely hooks like hurricane season, college move-in, and non-toxic living, and placed real patient stories in national health and lifestyle outlets. AM PR also used newswire releases and steady earned coverage to strengthen how AI platforms describe RealTime, and began building an affiliate pipeline with wellness, home, and parenting publications.




